Targeting Codon 61 Mutations in Melanoma & AML: High-Purity Mutant Proteins and Lentiviral Systems for Next-Generation RAS-Inhibitor Development.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for NRAS drug discovery. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen (Mutant & WT) | NRAS Q61R/Q61K/G12D Mutant & WT Recombinant Protein High purity (>95%), Endotoxin <1EU/µg. Sequence verified. Suitable for SPR, ITC, and DSC. |
View NRAS Products |
| Gene Delivery | NRAS Q61R/Q61K Lentivirus Premade Particles High-titer (>10^8 TU/mL) for stable melanoma/AML cell line construction. Preserves physiological palmitoylation. |
View NRAS Products |
| Benchmark Ab | Anti-NRAS Recombinant Rabbit mAb Sequence-verified positive control for Western Blot, IP, and IF. |
View NRAS Products |
| Validator | NRAS siRNA Set (3 unique targets) For knockdown verification and specificity controls in cellular assays. |
View NRAS Products |
| Related Target: KRAS | KRAS (WT, G12C, G12D) Pan-RAS selectivity counter-screening and subfamily specificity assays. |
View KRAS Products |
| Related Target: BRAF | BRAF (V600E) Downstream MAPK pathway node for combination therapy studies. |
View BRAF Products |
| Related Target: SOS1 | SOS1 Ras Activator Guanine nucleotide exchange factor (GEF) for PPI and displacement assays. |
View SOS1 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Differentiating NRAS mutants from WT & KRAS/HRAS | High-purity mutant panel (Q61R, Q61K, Q61L, G12D) strictly verified by mass spectrometry and sequence analysis. |
| Nucleotide Exchange Assay Interference | Proteins produced with optimized nucleotide loading states (nucleotide-free or native) for SOS1 biochemical screening. |
| Cellular Membrane Localization | Lentivirus system for stable integration ensuring proper post-translational palmitoylation and membrane anchoring. |
| Isoform Cross-reactivity | Pan-RAS assay panel (NRAS/KRAS/HRAS) with identical tags/purities for consistent selectivity profiling. |
| Lack of Controls | Clinical Benchmark Antibodies included for western blot, IP, and cellular assay baselines. |
| False Positives in Cellular Assays | Validated siRNA included for specificity checks and target degradation validation. |
Live NRAS R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
NRAS represents a critical frontier in RAS biology, with Q61 mutations driving 20-30% of cutaneous melanomas and 10-15% of acute myeloid leukemia (AML). Unlike KRAS G12C, NRAS lacks a reactive cysteine at position 61, rendering covalent inhibitor strategies ineffective and necessitating non-covalent allosteric inhibitors or targeted protein degradation approaches. The competitive landscape is rapidly evolving toward pan-RAS inhibitors capable of targeting active GTP-bound states, alongside combination regimens with MEK/ERK inhibitors to combat feedback activation. As first-generation NRAS-specific agents enter Phase I/II trials, the demand for sophisticated biochemical assays—particularly nucleotide-exchange and protein-protein interaction assays—has intensified to differentiate mechanisms of action.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Small Mol (Pan-RAS) | Revolution Medicines, BridgeBio | Melanoma, Solid Tumors | Selectivity Assay (Need High-Purity Mutant vs WT Proteins) |
| Small Mol (Mutant-Specific) | Kinnate Biopharma, Novartis | Melanoma (Q61X), AML | Binding / Exchange Assays (Need Nucleotide-free NRAS Mutants) |
| SOS1 / SHP2 Inhibitor (Indirect) | Boehringer Ingelheim, Novartis, Sanofi | NRAS-mutant Melanoma, Colorectal | PPI Assay (Need GDP-loaded NRAS + SOS1 complex for displacement screening) |
| PROTAC / Degrader | Arvinas, Berylline | Colorectal Cancer, Melanoma | Degradation Assay (Need Lentivirus for Stable Cell Lines) |
| TCR-T / Cancer Vaccine | Moderna, BioNTech, various | Solid Tumors | Neoantigen Presentation (Need Full-length ORF for delivery) |
Molecular Differentiation & Assay Strategy
Key Differentiation Dimensions
-
Nucleotide State Selectivity (GTP vs GDP): Best-in-class molecules must selectively bind the active GTP-bound state (NRAS-GTP). Assay strategy includes differential scanning calorimetry (DSC) for thermal shift and surface plasmon resonance (SPR) using pre-loaded GTPγS NRAS proteins. TarMart provides HPLC-verified GTPγS/GDP pre-loaded mutant proteins (Q61R, Q61K) ensuring nucleotide state homogeneity.
-
Membrane Localization Dependence (Palmitoylation): NRAS requires palmitoylation for membrane anchoring. Standard E. coli-expressed proteins lack this modification; mammalian cell-expressed lentivirus systems are essential for stable cell line construction and subcellular localization studies. TarMart's NRAS Q61R lentivirus preserves native lipid modifications.
-
SOS1 Affinity & Nucleotide Exchange Inhibition: Indirect inhibitors block SOS1-mediated nucleotide exchange. Assay strategies include FRET or AlphaLISA for NRAS-GDP/SOS1 binding and BODIPY-GTPγS fluorescence enhancement for exchange rate measurement. TarMart offers high-purity NRAS Q61R protein (GST-tagged) for SPR analysis of SOS1 binding kinetics.
-
Isoform Selectivity (NRAS vs KRAS/HRAS): Pan-RAS inhibitors require balanced activity, while NRAS-specific inhibitors must avoid KRAS off-target toxicity. Parallel testing of a RAS isoform panel (NRAS Q61R, KRAS G12C, HRAS Q61R) is critical. TarMart provides a three-isoform mutant protein panel with uniform tag systems (GST or His-tag) to eliminate tag-induced binding bias.
Recommended Assay Workflow
- Primary Screen (Biochemical): SPR primary screen using NRAS Q61R-GST protein (GTPγS-loaded) to exclude GDP-bound compounds; DSC validation for thermal shift (ΔTm) correlation.
- Secondary Validation (Selectivity): Parallel testing of KRAS G12C and HRAS Q61R proteins to ensure >10-fold selectivity window; counter-screen with WT NRAS for mutation specificity.
- Cellular Functional Validation: Use NRAS Q61R Lentivirus to construct A375 melanoma stable cell lines (replacing endogenous NRAS); Western blot for pERK1/2 inhibition (downstream pathway readout); siRNA knockdown for target specificity (using TarMart siRNA set).